相关研究报告 《内需提振预期强化，关注政策改善 可期—行业投资策略》-2025.5.8 《一季报白酒稳健增长，零食新品红 利表现突出—行业周报》-2025.5.5 《基金持仓更加集中，零食板块表现 较好—行业周报》-2025.4.27 白酒底部建议加配，大众品三条思路选股 ——行业周报 食品饮料 2025 年 05 月 11 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -36% -24% -12% 0% 12% 24% 2024-05 2024-09 2025-01 食品饮料 沪深300 zhangsimin@kysec.cn 证书编号：S0790123070080 核心观点：承压基调下的边际改善 5 月 5 日-5 月 9 日，食品饮料指数涨幅为 1.8%，一级子行业排名第 19，跑输沪 深 300 约 0.2pct，子行业中保健品（+5.1%）、烘焙食品（+4.2%）、预加工食品 （+2.5%）表现相对领先。上市公司财报披露结束后，市场进入业绩真空期，市 场风险偏好提升，食品饮料跑输大盘。往 2025 年全年展望，食品饮料行业主线 仍是消费复苏。2025 年我们更多期望经济活跃度提升带来商务消 ...

Group 1 - The event "I am a shareholder | Entering the Shanghai-listed company - Gansu Guofang Industrial and Trade (Group) Co., Ltd." was held to encourage investors to exercise their shareholder rights and improve investor relations management [2] - Guofang Group, established in 1996 and listed on the Shanghai Stock Exchange in September 2017, has evolved from a single department store into a regional commercial chain leader covering various formats such as shopping centers, supermarkets, and outlets [2] - During the event, investors visited Guofang Group's headquarters and flagship project, gaining insights into the company's operational details, including planning adjustments, brand layout, refined operations, and digital facility applications [2] Group 2 - In a discussion session, the company emphasized its strategies to enhance profitability and core competitiveness through optimizing business formats and strengthening supply chain management amid consumer recovery [3] - The company believes that regional retail enterprises possess unique investment value due to their local advantages and refined operations in the context of consumer segmentation [3] - The event concluded with positive feedback from participants, highlighting the importance of market feedback for continuous operational optimization and better performance for investors [3]

食品饮料：五一假期消费市场活 跃，带动餐饮市场恢复 2025 年 5 月 9 日 看好/维持 食品饮料 行业报告 根据商务部 5 日发布的数据显示，"五一"假期全国消费市场繁荣活跃。 据商务部商务大数据监测，假期全国重点零售和餐饮企业销售额同比增长 6.3%。其中餐饮文旅市场红火，假期全国重点监测餐饮企业销售额同比增长 8.7%，显示出较强的恢复趋势。 今年五一整体呈现文旅消费双旺的局面，根据去哪儿统计数据，"五一" 假期县城成为"反向旅游"最火目的地。平台上酒店预订遍布 1230 个县， 县城酒店预订量同比增长 30%。从客源地看，一线和新一线城市居民占比超 过六成。旅游消费的旺盛直接推动餐饮市场的恢复，根据商务部统计，假期 全国重点监测餐饮企业销售额同比增长 8.7%，较 2025 年春节全国重点零售 和餐饮企业销售额同比增长 4.1%的增速快 4.6 个百分点，显示出强劲的恢 复。 五一假期呈现的消费市场活跃，我们认为与各地落实中央促进消费内需 政策加大对内需的刺激力度有关，餐饮受到旅游带动呈现较好的恢复。我们 认为随着促内需政策的进一步落实，消费会有进一步的恢复。特别是跟旅游、 文化产业相关的餐饮行业 ...

日本政府官员：在三月家庭支出中看到一些消费复苏的迹象，消费者在食品支出方面仍然节俭。 ...

Group 1 - The Federal Reserve's upcoming interest rate decision is highly anticipated, with a 96.9% probability of maintaining current rates, indicating that the market has already priced in the expectation of no change [3] - The real focus lies in Fed Chair Powell's communication style; a hawkish tone could pressure the stock market, while a more dovish signal might boost market confidence [3] - Domestic consumption data from the recent May Day holiday shows 314 million travelers generating 180.27 billion yuan in spending, reflecting a year-on-year growth of 6.4% and 8.0%, which exceeds expectations and signals strong domestic demand [6] Group 2 - Political dynamics in the U.S. are creating uncertainty, as Pence's criticism of Trump highlights the deep divisions within American politics, which could lead to volatility in capital markets [8] - Concerns are rising in the domestic futures market, with reports suggesting that retail investors' positions are being closely monitored, indicating a level of anxiety among market participants [9] - A three-dimensional observation framework is suggested, focusing on the Fed's decision-making paths, the sustainability of domestic consumption recovery, and the tension between technical market adjustments and favorable policies [11] Group 3 - The interplay between the consumption surge during the May Day holiday and potential policy support may indicate resilience in the Chinese economy, suggesting a possible new breakthrough [13] - Maintaining independent thinking amidst information overload is emphasized as a crucial strategy for market participants to navigate through economic cycles [13]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with some companies showing significant profit growth while facing challenges from high inventory and pricing pressures. The outlook for 2025 appears more optimistic due to easing macroeconomic factors and supportive policies [3][5][6]. Group 1: Market Performance - The A-share market saw major indices rise, with the Chinese Medicine ETF (560080) increasing by 0.19% and trading volume exceeding 26 million yuan, indicating active trading [1]. - Among the 49 constituent stocks of the Chinese Medicine ETF, 24 reported positive net profit growth, representing approximately 49% of the total [3]. Group 2: Company Performance - Notable profit growth was observed in companies such as Jilin Aodong (+260%), Jiaying Pharmaceutical (+197%), and Buchang Pharmaceutical (+170%) [3]. - The financial performance of several companies showed varied results, with Jilin Aodong reporting a 27.7% decline in revenue but a 259.8% increase in net profit [4]. Group 3: Industry Outlook - The Chinese medicine industry is expected to face challenges in 2024 due to high baselines and inventory digestion, but a recovery is anticipated in 2025 as macroeconomic conditions improve [5]. - Policy support, including the March 2025 guidelines for enhancing Chinese medicine quality, is expected to stimulate innovation and improve market conditions [5][6]. Group 4: Valuation and Investment Opportunities - The current valuation of the Chinese Medicine Index is at a price-to-earnings ratio of 25.77, which is below the 74.1% threshold of the past decade, indicating a relatively low valuation [8]. - Investors are encouraged to consider the Chinese Medicine ETF (560080) for potential rebound opportunities in the market [10].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [50]. Core Insights - The chemical agents and blood products sectors showed outstanding performance in 2024, while the CXO and medical services (hospitals) sectors reported positive growth in both revenue and profit for Q1 2025 [4][5]. - As of April 30, 2025, among 467 selected A-share biopharmaceutical companies, 28 companies reported revenue growth exceeding 30% for 2024, while 50 companies had growth over 20% [4]. - In Q1 2025, 24 companies achieved revenue growth greater than 30%, and 100 companies reported profit growth exceeding 30% [4]. Summary by Sections Industry Performance - In 2024, the chemical agents and blood products sectors maintained positive growth in both revenue and profit [5]. - For Q1 2025, the CXO and medical services sectors also reported positive growth in revenue and profit [5]. Investment Strategy - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery" as key investment themes [7]. - Recommended companies for "innovation" include BeiGene, Dongcheng Pharmaceutical, and others [7]. - For "going global," companies like Mindray Medical and Sinopharm are highlighted [7]. - In "equipment upgrades," companies such as Mindray Medical and Aohua Medical are suggested [7]. - Under "consumption recovery," companies like Puri Eye Hospital and Tongce Medical are noted [7]. Key Companies to Watch - **Nocera Health**: Achieved revenue of 1.009 billion yuan in 2024, with a 49% year-on-year increase in sales of its core product, Obinutuzumab [8]. - **Sihuan Pharmaceutical**: Maintained a stable performance with core products continuing to grow [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products expected to accelerate profit growth [13]. - **Aibao Medical**: The launch of its self-developed ICL lens is expected to drive significant revenue growth [23]. Industry News Highlights - BeiGene's Sonrotoclax new drug application has been accepted for review [30]. - Novartis' Lutetium-177 injection has been accepted for a new indication in China [31]. - Fuhong Hanlin signed a licensing agreement with Sandoz for HLX13 [33]. - BeiGene won a patent dispute, strengthening its market position for its BTK inhibitor [34].

Core Insights - The Labor Day holiday consumption showed robust growth despite high base effects, indicating a recovery in consumer spending, particularly in the retail and tourism sectors [1][10] - Key retail and catering enterprises reported a year-on-year sales increase of 6.3%, up from 4.1% during the Spring Festival holiday, with tourism revenue also exceeding pre-pandemic levels [1][4] Consumption Trends by Category - Home appliances, automobiles, and communication equipment saw significant sales growth of 15.5%, 13.7%, and 10.5% respectively, driven by the "old for new" policy [2][11] - The catering sector experienced an 8.7% increase, benefiting from high consumer willingness to spend on experiential dining [2] - Jewelry sales improved due to lower base effects and fluctuating gold prices, with some brands reporting a shift from negative to positive growth [8] Regional Consumption Insights - Consumption growth was balanced across different city tiers, with key tourist cities performing strongly and lower-tier cities benefiting from increased foot traffic [3][9] - Major cities like Beijing and Shanghai outperformed the national average in consumption growth, supported by domestic tourism and favorable visa policies for inbound travelers [3][9] Tourism and Travel Data - Domestic tourism revenue grew by 8%, with total visitor numbers increasing by 6.4%, indicating a recovery to 123% of pre-pandemic levels [4][11] - Outbound travel saw a robust year-on-year growth of 21%, with Hong Kong and Macau leading the increase in inbound tourism [4] Industry Performance Highlights - The sports and leisure retail sector reported a 15% increase in sales, attributed to rising outdoor activities and favorable weather conditions [5] - The high-end liquor market faced challenges, with increased discounting in the mid-to-high price segments due to cautious consumer spending [6] - The restaurant sector showed varied performance, with some brands like Nayuki's Tea achieving significant growth in both dine-in and delivery sales [7] Box Office and Entertainment - The box office revenue during the holiday period fell sharply by 51% to CNY 747 million, primarily due to a lack of blockbuster films [8][11]

Core Insights - Yili's revenue and net profit have declined for the first time in 29 years, with 2024 revenue at 115.39 billion, down 8.24% year-on-year, and net profit at 8.45 billion, down 18.9% [2][3] - Liquid milk, the core revenue driver, saw a significant revenue drop of 10.5 billion, a decrease of 12% [2][3] - The company's chairman, Pan Gang, experienced a slight salary reduction from 21.79 million to 19.74 million amid the performance decline [2] Revenue Performance - Yili's total revenue for 2024 was 115.39 billion, a decrease of 8.24% year-on-year, with net profit at 8.45 billion, down 18.9% [3][6] - Liquid milk revenue fell to 75 billion, a decline of over 12%, while the cold drink segment also saw a significant drop, with revenue at 8.72 billion, down 18.41% [3][5] - The share of liquid milk in total revenue has decreased from over 75% in previous years to approximately 65% in 2024 [6] Strategic Challenges - Yili has been facing challenges in its core liquid milk business, which has historically driven growth [5][6] - The company has invested approximately 6.3 billion in the infant formula sector, acquiring a stake in Aoyou Dairy, but this segment has also shown declining revenue and profits [7][9] - Aoyou's revenue fell from 8.575 billion in 2021 to 7.382 billion in 2023, with net profit dropping significantly [9][11] Future Outlook - Despite current challenges, Pan Gang expressed confidence in a gradual recovery of the consumer market, anticipating a return to growth in 2025 [14] - Yili is exploring new product lines, including ready-to-drink tea and other food categories, although these currently contribute minimally to overall revenue [13][14] - The company believes there is still growth potential in the dairy market, particularly in lower-tier cities where consumption is expected to rise [14]